November 30, 2023 – Pharma Strategies | Zimbabwe, Zambia, South Africa

Phone: +263 (242) 741 308/9

Home
About Us
Our Work
Product Launches
News
Media
Links
Contact
Menu

Our next era

Our next era
weberfr8
Thu, 11/30/2023 – 14:03

Read more about Our next era

Print
PDF

November 30, 2023/by weberfr8

https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png 0 0 weberfr8 https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png weberfr82023-11-30 15:03:472023-11-30 15:03:47Our next era

PRODUCTS

UperioDecember 17, 2019 - 4:56 pm
TasignaDecember 2, 2019 - 2:40 pm
GalvusDecember 2, 2019 - 2:19 pm
AfinitorDecember 2, 2019 - 2:09 pm

TAGS

Antidiabetics Blood Pressure Cancer Galvus Galvus Met Malaria Novartis Oral Antidiabetics Osteoarthritis Read more about A cancer patient gets a new lease on life Read more about A legacy of blood cancer innovation Read more about A partnership against epilepsy Read more about Empowering the next generation of healthcare leaders Read more about Every number has a story – my journey to Novartis as a Refugee Read more about FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade Read more about FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer Read more about Going upstream to improve heart health in Philadelphia Read more about Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions Read more about Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer Read more about New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients Read more about Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024 Read more about Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Read more about Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration Read more about Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben Read more about Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) Read more about Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer Read more about Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence Read more about Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer Read more about Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial Read more about Novartis presentation at J.P. Morgan Healthcare Conference 2025 Read more about Novartis ranks first in 2024 Access to Medicine Index Read more about Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) Read more about Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Read more about Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer Read more about Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML Read more about Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML Read more about Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH Read more about Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd. Read more about Novartis statement on Maximum Fair Price for Entresto Read more about Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth Read more about Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day Read more about Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab Read more about Violence against innocent people runs counter to our work to improve human health Read more about Water project revives rural community in India Rheumatoid Arthritis

MENU

Home
About Us
Our Work
Product Launches
News
Media
Links
Contact

Calendar

November 2023
M	T	W	T	F	S	S
« Oct				Dec »
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

NOVARTIS NEWS

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfrontFebruary 11, 2025 - 8:19 am

ADDRESS

Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe

CALL US

+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm

Gallery

UperioDecember 17, 2019 - 4:56 pm
TasignaDecember 2, 2019 - 2:40 pm

© Copyright - Pharma Strategies | Zimbabwe